Counterpoint: Prevention of cytomegalovirus (CMV) infection and CMV disease in recipients of solid organ transplants: The case for prophylaxis

被引：32

作者：

Snydman, DR

机构：

[1] Tufts Univ New England Med Ctr, Div Geog Med & Infect Dis, Boston, MA 02111 USA

[2] Tufts Univ New England Med Ctr, Dept Med, Boston, MA 02111 USA

[3] Tufts Univ, Sch Med, Boston, MA 02111 USA

来源：

CLINICAL INFECTIOUS DISEASES | 2005年 / 40卷 / 05期

关键词：

D O I：

10.1086/427509

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

[No abstract available]

引用

页码：709 / 712

页数：4

共 44 条

[1] Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis [J].

Akalin, E ;

Sehgal, V ;

Ames, S ;

Hossain, S ;

Daly, L ;

Barbara, M ;

Bromberg, JS .

AMERICAN JOURNAL OF TRANSPLANTATION, 2003, 3 (06) :731-735

[2] Viral escape and T-cell immunity during ganciclovir treatment of cytomegalovirus infection: Case report of a pancreatico-renal transplant recipient [J].

Benz, C ;

Holz, G ;

Michel, D ;

Awerkiew, S ;

Dries, V ;

Stippel, D ;

Goeser, T ;

Busch, DH .

TRANSPLANTATION, 2003, 75 (05) :724-727

[3] Development of cytomegalovirus resistance to ganciclovir after oral maintenance treatment in renal transplant recipient [J].

Bienvenu, B ;

Thervet, E ;

Bedrossian, J ;

Scieux, C ;

Mazeron, MC ;

Thouvenot, D ;

Legendre, C .

TRANSPLANTATION, 2000, 69 (01) :182-184

[4] THE INFLUENCE OF HLA A-B-DR MATCHING ON CYTOMEGALOVIRUS DISEASE AFTER RENAL-TRANSPLANTATION - EVIDENCE THAT HLA-DR7-MATCHED RECIPIENTS ARE MORE SUSCEPTIBLE TO CYTOMEGALOVIRUS DISEASE [J].

BLANCHO, G ;

JOSIEN, R ;

DOUILLARD, D ;

BIGNON, JD ;

CESBRON, A ;

SOULILLOU, JP .

TRANSPLANTATION, 1992, 54 (05) :871-874

[5] Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients [J].

Boivin, G ;

Goyette, N ;

Gilbert, C ;

Roberts, N ;

Macey, K ;

Paya, C ;

Pescovitz, MD ;

Humar, A ;

Dominguez, E ;

Washburn, K ;

Blumberg, E ;

Alexander, B ;

Freeman, R ;

Heaton, N ;

Covington, E .

JOURNAL OF INFECTIOUS DISEASES, 2004, 189 (09) :1615-1618

[6] Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients [J].

Brennan, DC ;

Garlock, KA ;

Singer, GG ;

Schnitzler, MA ;

Lippmann, BJ ;

Buller, RS ;

Gaudreault-Keener, M ;

Lowell, JA ;

Shenoy, S ;

Howard, TK ;

Storch, GA .

TRANSPLANTATION, 1997, 64 (12) :1843-1846

[7]

Brennan DC, 1996, ANN INTERN MED, V124, P693, DOI 10.7326/0003-4819-124-7-199604010-00015

[8]

Corales R, 2000, Transpl Infect Dis, V2, P133, DOI 10.1034/j.1399-3062.2000.020306.x

[9]

Das A, 2003, PHARMACOECONOMICS, V21, P469

[10] Prophylaxis for CMV should not now replace pre-emptive therapy in solid organ transplantation [J].

Emery, VC .

REVIEWS IN MEDICAL VIROLOGY, 2001, 11 (02) :83-86

← 1 2 3 4 5 →